Haridwar Today

DelveInsight’s “Myopia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myopia, historical and forecasted epidemiology as well as the Myopia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myopia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myopia Market Forecast

Some of the key facts of the Myopia Market Report: 

• The Myopia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In October 2023, Vyluma announced favorable initial results from the second phase of the Phase III Childhood Atropine for Myopia Progression (CHAMP) clinical trial of NVK002. NVK002 is a preservative-free eye drop under investigation for the management of myopia in children aged three to 17. These drops are designed to be administered nightly.

• In a study conducted by Nemeth J. et al. titled “Update and Guidance on Management of Myopia” (2021), it was cited that among White European children, the average annual progression rates for myopia and axial length were -0.41 D and -0.30 mm, respectively, from 6 to 16 years of age, and -0.16 D and 0.15 mm, respectively, from 12 to 22 years of age.

• Key Myopia Companies: Sydnexis, Inc., Laboratorios Sophia S.A de C.V., Vyluma, Inc., Hai Yen Eye Care, Qilu Pharmaceutical Co., Ltd., Eyenovia Inc., Santen Pharmaceutical, University of Waterloo, iVeena Delivery Systems, Ocumension (Hong Kong) Limited, Cloudbreak Therapeutics, LLC, Bayer, Novartis, Center For Excellence In Eye Care, LENZ Therapeutics, Inc, and others

• Key Myopia Therapies: SYD-101, Alleance®, NVK-002, BHVI1, QLM3004, Atropine 0.1%, DE-127, ClearCare, IVMED 85, OT-101 Ophthalmic Solution, CBT-009, VEGF Trap-Eye (BAY86-5321), Ranibizumab, ketorolac (Acular LS), Aceclidine + Brimonidine, and others

• The Myopia epidemiology based on gender analyzed that there are more cases of mild myopia as compared to moderate and severe myopia

• The Myopia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myopia pipeline products will significantly revolutionize the Myopia market dynamics.

Myopia Overview

Myopia, commonly known as nearsightedness, is a refractive error of the eye where close objects can be seen clearly, but distant objects appear blurry. This occurs when the eyeball is too long or the cornea (the clear front surface of the eye) is too curved. As a result, light rays entering the eye are focused in front of the retina instead of directly on it.

Get a Free sample for the Myopia Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/myopia-market

Myopia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myopia Epidemiology Segmentation:

The Myopia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Myopia

• Prevalent Cases of Myopia by severity

• Gender-specific Prevalence of Myopia

• Diagnosed Cases of Episodic and Chronic Myopia

Download the report to understand which factors are driving Myopia epidemiology trends @ Myopia Epidemiology Forecast

Myopia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myopia market or expected to get launched during the study period. The analysis covers Myopia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myopia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myopia Therapies and Key Companies

• SYD-101: Sydnexis, Inc.

• Alleance®: Laboratorios Sophia S.A de C.V.

• NVK-002: Vyluma, Inc.

• BHVI1: Hai Yen Eye Care

• QLM3004: Qilu Pharmaceutical Co., Ltd.

• Atropine 0.1%: Eyenovia Inc.

• DE-127: Santen Pharmaceutical

• ClearCare: University of Waterloo

• IVMED 85: iVeena Delivery Systems

• OT-101 Ophthalmic Solution: Ocumension (Hong Kong) Limited

• CBT-009: Cloudbreak Therapeutics, LLC

• VEGF Trap-Eye (BAY86-5321): Bayer

• Ranibizumab: Novartis

• ketorolac (Acular LS): Center For Excellence In Eye Care

• Aceclidine + Brimonidine: LENZ Therapeutics, Inc

Discover more about therapies set to grab major Myopia market share @ Myopia Treatment Landscape

Scope of the Myopia Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Myopia Companies: Sydnexis, Inc., Laboratorios Sophia S.A de C.V., Vyluma, Inc., Hai Yen Eye Care, Qilu Pharmaceutical Co., Ltd., Eyenovia Inc., Santen Pharmaceutical, University of Waterloo, iVeena Delivery Systems, Ocumension (Hong Kong) Limited, Cloudbreak Therapeutics, LLC, Bayer, Novartis, Center For Excellence In Eye Care, LENZ Therapeutics, Inc, and others

• Key Myopia Therapies: SYD-101, Alleance®, NVK-002, BHVI1, QLM3004, Atropine 0.1%, DE-127, ClearCare, IVMED 85, OT-101 Ophthalmic Solution, CBT-009, VEGF Trap-Eye (BAY86-5321), Ranibizumab, ketorolac (Acular LS), Aceclidine + Brimonidine, and others

• Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies

• Myopia Market Dynamics: Myopia market drivers and Myopia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Myopia Unmet Needs, KOL’s views, Analyst’s views, Myopia Market Access and Reimbursement 

To know more about Myopia companies working in the treatment market, visit @ Myopia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Myopia Market Report Introduction

2. Executive Summary for Myopia

3. SWOT analysis of Myopia

4. Myopia Patient Share (%) Overview at a Glance

5. Myopia Market Overview at a Glance

6. Myopia Disease Background and Overview

7. Myopia Epidemiology and Patient Population

8. Country-Specific Patient Population of Myopia 

9. Myopia Current Treatment and Medical Practices

10. Myopia Unmet Needs

11. Myopia Emerging Therapies

12. Myopia Market Outlook

13. Country-Wise Myopia Market Analysis (2019–2032)

14. Myopia Market Access and Reimbursement of Therapies

15. Myopia Market Drivers

16. Myopia Market Barriers

17.  Myopia Appendix

18. Myopia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/